Collegium Pharmaceutical, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:COLL
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 505 out of 921
Universe
Global Universe 11243 out of 16216
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Collegium Pharmaceutical, Inc. |
29.6
Medium
|
505 out of 921 |
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. |
32.1
High
|
622 out of 921 |
Strides Pharma Science Ltd. |
32.7
High
|
653 out of 921 |
Calliditas Therapeutics AB |
34.4
High
|
742 out of 921 |
Sino Biological Inc. |
34.6
High
|
753 out of 921 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Collegium Pharmaceutical, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Collegium Pharmaceutical, Inc.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted Collegium Pharmaceutical, Inc.'s ESG Risk Rating in the last three years
Highest Controversy Level
![blurred controversy level](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-level-blur.jpg)
Contributing Events
![blurred controversy events](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-events-blur.jpg)
Highest Controversy Events Locations
![world map blurred](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-events-map-blur.jpg)